5/17/2013 myelodysplastic syndrome: a pathologist [s ... stain showed many ring sideroblasts...
TRANSCRIPT
5/17/2013
1
Myelodysplastic Syndrome: a pathologist’s perspective
Kajal Sitwala, MD, PhD
MYELODYSPLASTIC SYNDROMES: Part 1 – Example MDS cases coming into our practice over the last several weeks Part 2 – Review of MDS definition, features, morphology, and biology
Case 1: -64 y.o. man with longstanding low back pain (unrelated) -MRI showed abnormal bone marrow signal referred to Hematology -Had normocytic anemia dating back 15 years -Bone marrow biopsy showed fairly normal overall cellularity, but relative expansion in erythropoiesis. Iron stain showed many ring sideroblasts -Diagnosis of RARS (low-grade MDS) -Refractory Anemia with Ring Sideroblasts -Interval treatment supportive (erythropoietin to boost RBC production) -Follow-up bone marrow
Dyserythropoiesis in aspirate smear
Ring sideroblasts (special stain of aspirate smear) Hypercellularity; odd megakaryocytes, but not typical for MDS
5/17/2013
2
Diagnosis:
Persistent RARS -No increase in blasts -Frank dysplasia still limited to the erythroid lineage -Cytogenetic analysis showed same abnormality as before (+8) -Trisomy 8 can be seen in myeloid disorders including MDS and AML -For RARS, it’s worse prognosis to see it (versus normal karyotype) -Flow cytometry: main contribution is confirming no increase in blasts -Mild aberrancy of CD56 co-expression on maturing granulocytes and monocytes -(supportive finding, not enough to definitively diagnose MDS) -Recently, MDS-RARS shown to have strong association with gene mutation: -Haploinsufficiency of SF3B1
Case 2: -62 y.o. man with anemia and thrombocytopenia -Bone marrow showed RAEB-1 (high-grade MDS) -Refractory Anemia with Excess Blasts -Treatment/management course complicated by cold agglutinin disease and transfusion refractoriness -Recently, transfusion requirements became too severe to manage supportively, hospitalized for aggressive chemotherapy -Bone marrow performed to assess response
Peripheral blood: Granulocyte with mature, clumped chromatin but lack of granulation or nuclear lobation (Pseudo-Pelger-Huet)
Increased blasts in aspirate smear
Hypercellular but loose marrow (fibrosis), Dysplastic megakaryocytes
Diagnosis:
Persistent MDS, now best classified as RAEB-2 -In subsequent bone marrows, I only reclassify MDS if worse -improvements are described, but disease isn’t “downgraded” as a new MDS subtype -14% blasts in differential count of aspirate smear -Reticulin stain confirmed the presence of fibrosis -Historically normal karyotype in leukemia cells; not repeated with this specimen -Flow cytometry with 15% blasts, similar phenotype as prior cells -Patient given even more aggressive treatment (AML induction), however, disease is persisting
5/17/2013
3
Case 3: -83 y.o. woman with history of MDS dating back to 2008 -When seen here in 2010, classified as RCMD -Refractory Cytopenia with Multilineage Dysplasia -2010 bone marrow with similar cytogenetic abnormalities, still low-grade (no increase in blasts -Since then, CBC counts have held pretty steady with lenolidamide treatment -uniquely efficacious in cases involving chromosomal deletions on 5q -Some concern with low hemoglobin values, so bone marrow reassessed
Basophilic stippling in peripheral blood
Dyserythropoiesis in aspirate smear Small and hypolobated megakaryocytes in aspirate smear
Ring sideroblasts in aspirate smear
Diagnosis:
Persistent RCMD -Cytogenetics unchanged over past 5 years -46,XX,del(5)(q13q33),add(11)(q23)[19]/46,XX[1] -doesn’t fit for isolated 5q deletion (‘’5q-minus syndrome’’) but some features overlap -often, dramatic worsening (e.g. increase in blasts) corresponds with clonal evolution -Flow cytometry: increased basophils, light scatter changes (but no aberrant phenotype) -No increase in blasts -Later: discuss role of lenolidamide in 5q deleted cases
5/17/2013
4
A group of clonal hematopoietic stem cell
diseases characterized by cytopenias,
dysplasia, ineffective hematopoiesis, and
increased risk of developing acute
myeloid leukemia.
-Principally a disease of older adults -Disorder of HSCs and their microenvironment
MDS 1953 – Knudson hypothesis: cancer results from accumulated DNA mutations 1990’s – 2-hit model of leukemia
Adapted from WHO 2008
Class I mutations Class II mutations
FLT3-ITD FLT3-TKD
JAK2-V617F KIT mutations RAS mutations
PML-RARA AML1-ETO
CBF -MYH11 CEBPA mutations NPM1 mutations?
Proliferation advantage Survival advantage
Differentiation arrest clonogenicity
AML
General (simplified) model of myeloid malignancies
Proliferation advantage Survival advantage
Differentiation arrest clonogenicity
AML
Myeloproliferative disorders Myelodysplastic syndromes
CLASS I CLASS II
So MDS is a stem cell neoplasm: but what does “immortalization” look like? Clonogenic, but not rapid, proliferation of stem cells (There is also increased apoptosis) Inability to complete differentiation and leave marrow Hallmark of MDS – peripheral blood cytopenias PLUS bone marrow hypercellularity In contrast to MPDs… Rapid proliferation but complete differentiation – cells accumulate in both places (clinical presentation from tumor burden rather than loss of function) Or acute leukemia… Proliferation and lack of differentiation: blasts in bone marrow and blood
Programs of self-renewal and differentiation use some of the same molecules (transcription factors)
-Clonogenicity: (Can’t see whether a cell will keep dividing or not)
-Hypercellularity
-Maturation arrest: (Marrow is full of precursors anyhow)
-Skew toward immaturity As Hematopathologists, what we SEE is morphologic abnormalities that result From these molecular processes
Normal Erythroid Maturation (ASH image Bank)
5/17/2013
5
Normal Megakaryocyte making platelets (ASH image Bank)
Pictures of normal hematopoietic elements
A blood smear and a marrow, or just a single marrow picture
Normal Leukocytes in peripheral blood (ASH image Bank)
Predictions about dysplasia, based on concept of “maturation arrest” – 1. immaturity of any kind a. cells that are more like a precursor form b. failure to develop characteristics of final state 2. dyssynchrony between different elements/split personality as far as further cell division 3. just plain weird
1a. Immaturity
Excess blasts Erythroid immaturity (increase in early forms) Small megakaryocytes that have not divided the nucleus yet
Patient with RCMD (including 5q minus but with additional abnormalities) Patient with RCMD (including 5q minus but with additional abnormalities)
5/17/2013
6
Patient with RCMD (including 5q minus but with additional abnormalities) Patient with RCMD (including 5q minus but with additional abnormalities)
Patient with RAEB-1)
1b. Failure to finalize -lack of granulation in circulating neutrophils -lack of nuclear lobation in circulating neutrophils *mimic of harmless genetic state (Pelger-Huet anomaly)
Pseudo-Pelger Huet neutrophils with hypogranulation (ASH image Bank)
2. Dyssynchrony, or confusion about further division -Hemoglobinized cytoplasm with still immature nucleus -Nuclear budding in erythroid precursors -Megakaryocytes with completely separated nuclear lobes
5/17/2013
7
Patient with RAEB-1 Dysplastic erythroid precursor with hemoglobinization and large nucleus (ASH image Bank)
Dysplastic megakaryocytes with separation of nuclear lobes (ASH image Bank) Nuclear budding in erythroid precursor (ASH image Bank)
Patient with RCMD (core biopsy touch imprints)
3. Just plain weird -Ring sideroblasts -Megaloblastoid chromatin in erythroid precursors -Basophilic stippling in red blood cells -Dimorphic circulating red cell population -Vacuoles (especially erythroid precursors) *beware of MDS mimic – copper deficiency (sometimes caused by zinc toxicity)
5/17/2013
8
Patient with RCMD (including 5q minus but with additional abnormalities) Megaloblastoid chromatin (ASH image Bank)
Ring sideroblasts (ASH image Bank)
That “classification” was purely speculative, a tool to mentally account for dysplasia Are there any cases where we have pinpointed the connection between genes and dysplasia?
5q minus syndrome
Anemia – can be quite severe Normal to elevated platelet count; characteristic megakaryocytes Hypercellular marrow, variable erythroid dysplasia Female predominance – middle to older age
5q minus syndrome
1974 – Nature – clinical syndrome with chr 5 long arm deletion reported 2001 – WHO classification recognizes 5q- as distinct subtype of MDS 2002 – Blood – commonly deleted region narrowed to 40 genes by FISH/Southern 2007 – ASH plenary abstract – identification of candidate gene no biallelic deletions or point mutations in 40 genes – likely haploinsufficiency therefore reduction in gene expression could be exploited: RNA interference findings published: Ebert et al., Nature, January 2008 (Golub laboratory – Harvard)
5/17/2013
9
Ebert et al., Nature, January 2008
Megakaryocyte:erythroid ratio using markers CD41, glycophorin A
RPS14 participates in ribosomal synthesis RPS19 mutations found in 25% Diamond-Blackfan Anemia cases
Haploinsufficiency of ribosomal proteins: Phenotype of macrocytic anemia shows p53 dependence -Cell cycle arrest, failure to complete erythroid differentiation -Interestingly, 5q minus syndrome differs from other MDS by exhibiting erythroid hypoplasia Studies in mice prove the genotype:phenotype correlation for anemia Further research showed increased RPS14 levels after lenolidamide therapy But, doesn’t answer the whole question…megs are normal in those mice Also, DBA patients (RPS19) don’t have platelet or megakaryocyte problems
From Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype; Daniel T Starczynowski, et al Nature Medicine 16, 49–58 (2010) (obtained with permission)
microRNA: from non-coding parts of genome -regulate mRNA (coding parts of genome) However, another gene on 5q-, in fact the genes for two microRNAs, have
recently been shown to recapitulate the phenotype of small megs….
From Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype; Daniel T Starczynowski, et al Nature Medicine 16, 49–58 (2010) (obtained with permission)
Targets of these microRNAs are transcription factors (TiRAP, TRAF6), and these in turn Regulate level of interleukin-6 Increased IL-6 can recapitulate megakaryocyte phenotype Lenolidamide* reduces IL-6 levels But wait…didn’t they think lenolidamide worked by increasing RPS14 expression? But wait…there’s also the SPARC gene on 5q-, necessary for mouse hematopoiesis, lenolidamide increases its expression as well! *Thalidomide analog with many anti-cancer mechanisms in vitro and in vivo Genotype:phenotype correlations are real, but messy and redundant Hard to untangle, because of complexity of hematologic pathway, evolved in parallel to general embryogenic cascade
The genes used to regulate hematopoiesis are the same set of genes that determine body patterning during embryogenesis!
Fro
m W
ikip
edia
5/17/2013
10
The genes used to regulate hematopoiesis are the same set of genes that determine body patterning during embryogenesis! Human genes: -Used once to make our body (in utero), then over and over for the rest of our lives to make blood cells -HOXA9 is most upregulated gene in AML -Potent mediator of leukemia
cluster chromosome genes
HOXA chromosome 7 HOXA1, HOXA2, HOXA3, HOXA4, HOXA5, HOXA6, HOXA7, HOXA9, HOXA10, HOXA11, HOXA13
HOXB chromosome 17 HOXB1, HOXB2, HOXB3, HOXB4, HOXB5, HOXB6, HOXB7, HOXB8, HOXB9, HOXB13
HOXC chromosome 12 HOXC4, HOXC5, HOXC6, HOXC8, HOXC9, HOXC10, HOXC11, HOXC12, HOXC13
HOXD chromosome 2 HOXD1, HOXD3, HOXD4, HOXD8, HOXD9, HOXD10, HOXD11, HOXD12, HOXD13
Control
Hoxa9
Meis1
0
2000
4000
6000
8000
10000
12000
0 2 4 6 8day
ce
lls x
10
00
0
- 4-OHT
+ 4-OHT+ -
>-8-fold no change >8-fold
Slc18a1 Sox4
Auts2 Flt3
Dnajc10 A930001M12
Cd34 Pctk2 Amot Tgm3 Cradd
Rora Foxp1
B4galt4 Man1a
Lmo2 5830405N20
Pcnx Pdcd4 Pde7a
Fut8 Tox
Tcf4 Fndc3b
4931406I20 Map4k5
Bmp2k 9330182L06
Aff3 Camk2d
Il10rb 1110028C15
Pdk1 Usp12
Csf2ra Lhfpl2
Myo1e Ier3
4631426J05 Per2
Vcl Ctsc
Cpne2 Ifngr1 Dach1
Dfna5h Bpil2
Klf5 Crem
2900024C23 A130090K04
Hist1h1c Niban
Ebi2 Plxnd1 P2ry1 Trps1 Bcar3 Msr1
Frmd4b Ccl4
Osbpl3 Mrvi1 Gpr84 Ch25h
Rgs1 Gca
Mgll Zfp36l1
Hgf Id2
Thbs1
Cd34 Flt3
Gpr56
Csf2ra B2Galt6
Tgfbr3 Tlr4
72 96 120 h 72 96 120 h
Me
an+/
- 2
SD C
on
serv
atio
n S
core
Peak-widths from center of peak 0 1 2 3 4 5 6
Inpp5a gene exon
Meis1
Hoxa9
Vertebrate conservation
Hox Loci
MLL Polycomb
TALE factors
Common developmental genes (direct targets)
Body patterning/ Hematopoiesis/ Embryonic development Leukemogenesis
Context-specific downstream targets
WHO 2008 Myelodysplastic Syndromes:
Refractory cytopenia with unilineage dysplasia: Refractory anemia Refractory neutropenia Refractory thrombocytopenia Refractory anemia with ring sideroblasts
Refractory anemia with multilineage dysplasia
Refractory anemia with excess blasts
Myelodysplastic syndrome associated with isolated del(5q)
Myelodysplastic syndrome, unclassifiable
Childhood myelodysplastic syndrome provisional category: Refractory cytopenia of childhood
In the separate category of AML and Related Precursor Neoplasms:
Therapy-related myeloid neoplasms (includes cases meeting morphologic MDS criteria)
Transformation from MDS: AML with myelodysplasia-related changes
Also a separate category: Myelodysplastic/Myeloproliferative Neoplasms
Summary – A pathologist’s perspective on MDS -WHO classification is our guide to approaching the diagnosis -Threshold is key -CBC information is the predictor -This is how patients come to attention of hematology, then to us -Morphology and cytogenetics make up our toolset -Flow cytometry can sometimes contribute -FISH plays a more minor role than conventional karyotype -New studies support possible role for point mutations -The biology guides our understanding, and contextualizes morphology -And genetics holds (some of) the answers